Variations in apolipoprotein D and sigma non-opioid intracellular receptor 1 genes with relation to risk, severity and outcome of ischemic stroke by Håkan Lövkvist et al.
Lövkvist et al. BMC Neurology 2014, 14:191
http://www.biomedcentral.com/1471-2377/14/191RESEARCH ARTICLE Open AccessVariations in apolipoprotein D and sigma
non-opioid intracellular receptor 1 genes with
relation to risk, severity and outcome of ischemic
stroke
Håkan Lövkvist1,2,7*, Ann-Cathrin Jönsson3, Holger Luthman4, Katarina Jood5, Christina Jern5, Tadeusz Wieloch6
and Arne Lindgren1,2Abstract
Background: In experimental studies, the apolipoprotein D (APOD) and the sigma receptor type 1 (SIGMAR1) have
been related to processes of brain damage, repair and plasticity.
Methods: We examined blood samples from 3081 ischemic stroke (IS) patients and 1595 control subjects regarding
10 single nucleotide polymorphisms (SNPs) in the APOD (chromosomal location 3q29) and SIGMAR1 (chromosomal
location 9p13) genes to find possible associations with IS risk, IS severity (NIHSS-score) and recovery after IS (modified
Rankin Scale, mRS, at 90 days). Simple/multiple logistic regression and Spearman’s rho were utilized for the analyses.
Results: Among the SNPs analyzed, rs7659 within the APOD gene showed a possible association with stroke risk
(OR = 1.12; 95% CI: 1.01-1.25; P = 0.029) and stroke severity (NIHSS≥ 16) (OR = 0.70; 95% CI: 0.54-0.92; P = 0.009) when
controlling for age, sex and vascular risk factors for stroke. No SNP showed an association with stroke recovery (mRS).
Conclusions: We conclude that the SNP rs7659 within the APOD gene might be related to risk and severity of
ischemic stroke in patients.
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Stroke is a major cause of death and the main cause of
adult disability. Approximately 20 to 30% of all ischemic
stroke patients die in the acute stages of the stroke
episode while more than one third of those who survive
remain dependent of daily next-of-kin support or commu-
nity care six months after stroke onset [1,2]. Still, five years
after stroke onset, two thirds of the survivors have some
neurologic impairment and disability [3]. Recanalization of
occluded vessels after embolic stroke is the only therapeutic
intervention available to treat acute ischemic stroke (IS),
while no pharmacological treatment that stimulate brain
repair or plasticity and that might enhance recovery of lost* Correspondence: hakan.lovkvist@skane.se
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unless otherwise stated.function is at hand. However, rehabilitative training
such as task-oriented practice [4] and long-term progressive
resistance training [5], may enhance recovery of lost brain
functions.
The multifactorial and complex features of stroke
impose a considerable challenge for the understanding
of the pathology and for the development of new therapies.
Multiple environmental factors including co-morbidities
increase the risk of stroke [6]. Likewise, stroke severity is
dependent on the type of stroke, density of ischemia and
duration of vessel occlusion, and is also influenced by
several toxic mechanisms, most identified in experimental
animal models of stroke [7]. Finally, brain repair involves
mechanisms differentially activated in time and space, and
include inflammation, brain remodelling and relearning of
activated neural networks [8,9]. Genetic factors influence
the impact of these innate cellular mechanisms and envir-
onmental factors, affecting risk for stroke, as well as thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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outcome [10].
Previous clinical studies have shown that allelic
variants within the PDE4D gene, chromosome 9p21
and the AB0 locus may be associated with IS risk
[11-13]. Also variants in HDAC9, as well as in chromosome
6p21.1 and 9p21, have shown association with large vessel
IS [14-17], and variants in PITX2 and ZFXH3 may affect
cardioembolic stroke risk according to other studies made
[18,19]. In contrast to the situation regarding IS risk,
reports on genetic factors contributing to outcome
after stroke are scarce. However, a study has reported that
the apolipoprotein E (APOE) ε2 polymorphism might
contribute to variability in outcomes after hemorrhagic
stroke [20]. Likewise, an association was found between
polymorphisms of the COX-2 and Glycoprotein IIIa genes
on functional outcome 90-days after IS [21]. These studies
clearly demonstrate the potential of genetic analysis in
identifying mechanisms involved in functional recovery of
stroke patients. More recently, genetic variations in the
human dopamine system were associated with motor
learning after stroke [22]. This indicates the potential
of genetic analysis in identifying relevant mechanisms
involved in stroke and therapeutic targets.
The apolipoprotein D (APOD) has been suggested to be
related to stroke not only by virtue of its ability to influence
trafficking of lipids but also by modulating oxidative stress,
synaptic plasticity and cell death [23,24]. Moreover, APOD
appears to be associated with several neurological diseases
and normal ageing [25], schizophrenia [26], Alzheimer's
disease (AD) [27,28] and Parkinson’s disease (PD) [29].
APOD levels increase with age [30], with higher levels in
women than in men [25]. Also, in experimental models of
stroke [31] and trauma [32], the levels of APOD are
elevated. Polymorphisms of the APOD gene have been
associated with increased risk of AD [28,33]. The general
increase of APOD levels in a broad range of disease states
suggest that the protein may be induced in response to
stress. Indeed, APOD appears to be an anti-oxidant
[34] dependent on the integrity of the Met93 of this
lipoprotein [35]. In animal models of stroke, increased
APOD levels are correlated with better functional recovery,
implying a possible function of APOD in the repair
processes after stroke [31].
Whilst the apolipoproteins are trafficking lipids among
cells [23], the sigma receptor type 1 (SIGMAR1, sometimes
also denoted SIG1R or OPRS1) is involved in signalling and
trafficking of lipids and proteins within cells [36]. Through
these mechanisms the SIGMAR1 may modulate cell death
and brain plasticity in experimental models of stroke [37].
The SIGMAR1 appears to play a central role in central
nervous system (CNS) diseases since polymorphisms
in the SIGMAR1 gene are associated with depression [38],
schizophrenia [39] and alcoholism [40] as well as AD [41].With this background we aimed to investigate whether
polymorphisms in the APOD and SIGMAR1 genes influ-
ence stroke severity as well as functional outcome in
patients suffering from IS. By including a group of
control subjects we also assessed these polymorphisms’
possible impact on IS risk.
Methods
Study subjects
The study was approved by the ethical committee at Lund
University, Lund (application 543/2008). We included 2241
consecutive first-ever IS patients of all ages from Lund
Stroke Register (LSR) and 840 first-ever or recurrent IS
patients below 70 years of age from the Sahlgrenska
Academy Study on Ischemic Stroke (SAHLSIS), Gothenburg.
Both LSR and SAHLSIS have been described previ-
ously [42,43]. Patients were included if they had clinical
symptoms of IS, confirmed by CT or MR or autopsy of the
brain, provided DNA for analysis, and if they or their
next of kin had given informed consent to participate.
Exclusively for the IS risk association assessments we also
included control subjects from the same geographical
areas with age and gender distribution similar to those in
the IS cohort. The 1595 control subjects (929 from LSR,
666 from SAHLSIS) were randomly selected from Swedish
population registers from the same areas and matched for
age and gender to the patients. The SAHLSIS sample
included younger participants (with range 18–69 years)
than the LSR sample (with range 17 to 102 years). The
proportion of men was thus larger in the SAHLSIS sample
(Table 1).
Definition of stroke severity and stroke recovery
(outcome)
For LSR patients, initial stroke severity was assessed
using the NIH stroke scale (NIHSS) in the acute phase
after stroke onset [44]. For SAHLSIS patients, initial stroke
severity was assessed using the Scandinavian Stroke Scale
(SSS) [45]. These SSS scores were transformed to NIHSS
scores through the algorithm NIHSS = 25.68-0.43*SSS [46].
A NIHSS score of 8 or above but below 16 was considered
to indicate a moderately severe stroke, and a score of 16 or
above was considered to indicate a severe stroke [47].
For SAHLSIS, mRS at 3 months was assessed using the
original scale 0–5 at a follow-up visit with a neurologist.
For LSR, stroke outcome was assessed using Riksstroke
data at 3 months after stroke. We used a translation
algorithm to calculate mRS grades from a set of self-reported
functional outcome questions available in Riksstroke
data [48]. The Riksstroke data do not distinguish between
mRS-grades 0, 1 and 2. However, as mRS-grade 2 is regarded
as the upper limit for independence of help/support
and the patient disability information relevant for this
study is provided by mRS-grades 3, 4 and 5, we merged














Age, Median (min, max) 76 (17, 96) 76 (18, 102) 58 (18, 70) 58 (18, 69) 66 (17, 96) 69 (18, 102)
Male sex, Number (%) 529 (57) 1169 (52) 391 (59) 550 (66) 920 (58) 1719 (56)
Diabetes mellitus, n 925 2139 664 840 1589 2979
Number (%) 69 (8) 550 (26) 33 (5) 153 (18) 102 (6) 703 (24)
Hypertension, n 925 2183 665 829 1590 3012
Number (%) 438 (47) 1479 (68) 230 (35) 485 (58) 668 (42) 1964 (65)
Current smoking, n 927 2193 666 836 1593 3029
Number (%) 92 (10) 423 (19) 131 (20) 323 (39) 223 (14) 746 (25)
NIHSS at stroke onset, n – 1983 – 581 – 2564
0-7, Number (%) – 1482 (75) – 448 (77) – 1930 (75)
8–15, Number (%) – 338 (17) – 92 (16) – 430 (17)
16- , Number (%) – 163 (8) – 41 (7) – 204 (7)
mRS at 3 months, n – 1157 – 565 – 1722
0–2, Number (%) – 625 (54) – 435 (77) – 1060 (62)
3, Number (%) – 196 (17) – 80 (14) – 276 (16)
4, Number (%) – 111 (10) – 41 (7) – 152 (9)
5, Number (%) – 92 (8) – 2 (<1) – 94 (5)
Deceased, Number (%) – 133 (12) – 7 (1) – 140 (8)
LSR = Lund Stroke Register, SAHLSIS = the Sahlgenska Academy Study on Ischaemic Stroke, mRS =modified Rankin Scale, NIHSS = NIH stroke scale, N = gross
sample size, n = net sample size after removal of missing values. All percentages are based on net sample sizes.
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the original mRS grades 0–5, we added mRS grade 6 for
individuals who had died at follow up for both samples.
Phenotypes
Definitions of intermediate phenotypes diabetes mellitus,
hypertension and current smoking, and IS pathogenetic
subtypes (i.e. large vessel disease, LVD; small vessel
disease, SVD; and cardioembolic stroke, CE; have been
described previously [11,50,51].
Selection of genetic variants and genotyping
Seven SNPs in APOD and five SNPs in SIGMAR1
(or in the immediate vicinity of these regions) were
selected using two different criteria: (1) SNPs serving
as markers were selected based on their low pairwise
linkage disequilibrium and a population frequency of
5% or more for the two gene regions (N = 7); (2)
SNPs representing non-synonymous genetic variants
with low population frequency but still above 0.1%
in European populations were chosen based on their
probable impact on protein function (N = 6). One of
these latter non-synonymous variants, rs1800866 in
SIGMAR1, is frequent enough to also be used as a marker.
The genotypings were performed at our local lab in
Malmö, Sweden using Sequenom technology, except forrs76929107 at the APOD locus and rs1800866 at the
SIGMAR1 locus that were genotyped at LGC Genomics
(former KBioscience), UK (http://www.lgcgenomics.com),
using IPLEX on a MassARRAY platform (Sequenom, San
Diego, CA, USA).
We scored the minor allele count of each SNP, i.e. 2, 1
or 0, and used these in additive models. Monomorphic
SNPs were excluded from further analyses.
Statistical methods
All included SNPs were tested for possible departure
from Hardy-Weinberg equilibrium by chi-square test
with one degree of freedom. These tests were performed
on the control subjects included solely for the IS risk
association analyses.
The possible association of each selected SNP with IS risk
(i.e. IS patients versus control subjects) was analyzed by use
of simple logistic regression, and multiple logistic regression
controlling for age, gender, diabetes mellitus, hypertension
and current smoking [11]. For the stroke severity response
variable we used Spearman rank correlation as well as
simple and logistic multiple regression with dichotomized
stroke severity response (with risk category defined by
NIHSS ≥ 8 and NIHSS ≥ 16, respectively) [47]. We also
assessed functional outcome in a likewise manner (with risk
category defined as mRS ≥ 3).
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of the possible impact of polymorphisms on the NIHSS
and mRS scores, we were able to obtain effect measures
and P-values that were not distorted by incorrect
assumptions about these non-continuous variables.
SNP rs7659 was significantly associated with stroke
severity in a first-step test. We therefore performed
subsequent analyses involving subgroups including study
group, gender, and age (</≥70 years) [50,52]. SPSS softwareTable 2 Analysis of association between ischemic stroke risk


































*)All genotypes were conforming to the Hardy-Weinberg equilibrium criterion (with
except for rs11559048 that showed a significant Hardy-Weinberg disequilibrium (P <
**)ORs obtained by multiple logistic regression analysis controlling for covariates ag
***)Two additional APOD encoding SNPs, rs5954 and rs5955, were genotyped but n(PASW/SPSS, version 18, IBM Corporation, Armonk,




Table 2 displays (1) the frequencies of all ten non-
monomorphic SNPs for LSR and SAHLSIS joined together,







2695 0.51 (0.21-1.26) 0.58 (0.91-1.20)
9 P = 0.145 P = 0.491
-
2141 1.03 (0.92-1.16) 1.02 (0.90-1.16)
795 P = 0.615 P = 0.768
88
2420 0.95 (0.79-1.15) 0.85 (0.70-1.04)
286 P = 0.595 P = 0.120
8
1944 1.03 (0.91-1.16) 1.02 (0.89-1.16)
693 P = 0.675 P = 0.789
77
1475 1.00 (0.89-1.11) 0.98 (0.88-1.10)
887 P = 0.950 P = 0.779
153
2943 1.06 (0.74-1.51) 1.10 (0.75-1.59)
91 P = 0.761 P = 0.634
1
2710 1.90 (0.52-6.92) 2.23 (0.57-8.75)
10 P = 0.329 P = 0.251
-
769 1.00 (0.92-1.09) 1.01 (0.92-1.11)
1317 P = 0.966 P = 0.895
623
1306 1.11 (1.01-1.22) 1.12 (1.01-1.25)
1177 P = 0.038 P = 0.029
240
1576 0.99 (0.89-1.09) 0.99 (0.89-1.11)
981 P = 0.805 P = 0.884
164
P = 0.093 or more when using a chi-square test on the control subjects),
0.001).
e, gender, diabetes mellitus, hypertension and current smoking.
ot included in this study due to monomorphic traits.
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conformed to the Hardy-Weinberg equilibrium criterion
(Table 2). One SNP, rs7659 within the APOD gene region,
was associated with IS risk (OR = 1.11; 95% CI: 1.01-1.22;
P = 0.038 when tested by univariate analysis, and OR= 1.12;
95% CI: 1.01-1.25; P = 0.029 when using multiple logistic
regression analysis controlling for covariates age, gender,
diabetes mellitus, hypertension and current smoking).
However, none of these P-values were significant when
considering Bonferroni correction for multiple testing.
Stroke severity and functional outcome
The results of the assessments of the ten non-
monomorphic SNPs of APOD and SIGMAR1 against
stroke severity are presented in Table 3. Analyses using
Spearman’s Rho suggested that variations in one SNP,
the APOD-encoding rs7659, is associated with NIHSS
(Rho = −0.048; P = 0.023), while multiple logistic regression
considering a NIHSS cut-off point of 16 provided an
OR= 0.70; 95% CI: 0.54-0.92; P = 0.009. Also, an association
(OR = 0.65; 95% CI: 0.46-0.91; P = 0.012) between the
SIGMAR1 encoding rs12001648 and medium-severe
stroke onset risk (NIHSS ≥ 8) was found. When a sub-
group of patients aged 70 years or above was tested
against the severe IS onset indicator (defined as
NIHSS ≥ 16), an association between stroke severity
and variants of SNP rs7659 within the APOD region
was noticed (OR = 0.63; 95% CI: 0.45-0.88; P = 0.006).
These results are shown in Table 4. Still, none of
these tests implied any significant association whenTable 3 Analysis of association between stroke severity (NIHS
NIHSS score NIHSS; dichotomous indicator o







P-value OR (95% CI) P-value OR (9
SIGMAR1:
rs11559048 0.023 0.284 1.86 (0.44-7.79) 0.399 1.74 (0
rs1800866 -0.012 0.554 1.02 (0.87-1.22) 0.772 0.98 (0
rs12001648 -0.044 0.040 0.77 (0.56-1.05) 0.094 0.65 (0
rs7036351 0.000 0.984 1.04 (0.87-1.25) 0.670 0.99 (0
rs3808873 0.011 0.627 1.04 (0.88-1.23) 0.619 1.07 (0
APOD:
rs76929107 0.004 0.826 0.85 (0.50-1.46) 0.555 0.74 (0
rs5952 0.022 0.309 1.54 (0.38-6.18) 0.542 1.40 (0
rs34697430 0.011 0.599 1.07 (0.93-1.23) 0.334 1.08 (0
rs7659 -0.048 0.023 0.89 (0.77-1.04) 0.141 0.85 (0
rs823510 0.013 0.538 1.03 (0.88-1.21) 0.680 1.00 (0
Ischemic stroke patients from Lund Stroke Register and the Sahlgenska Academy S
NIHSS = NIH stroke scale. *) Cannot be estimated due to monomorphism among paconsidering Bonferroni-correction. However, when con-
sidering the pathogenetic stroke main subtype CE as a
subgroup for assessment we found SNP rs7659 to be
significantly associated with stroke severity defined by
the NIHSS > 16 cut point (OR = 0.59; 95% CI: 0.40-0.85;
P = 0.005; results shown in Table 4).
None of the ten non-monomorphic SNPs significantly
affected functional outcome after stroke (Table 5).
Discussion
With this large study sample comprising a total of 3081
IS patients we were able to perform analyses aimed to
find possible impact of selected polymorphisms encoding
for APOD and SIGMAR1 on (1) stroke severity and (2)
stroke outcome, respectively. By adding 1595 control sub-
jects not suffering any stroke onset from the same geo-
graphical areas and with the same age and gender
distribution as the IS patients, we have also been able to
examine possible effect of these polymorphisms on IS risk.
The conclusions from the non-parametric Spearman
correlation analyses (NIHSS and mRS-scores, respectively,
against SNP variations) were based upon P-values
obtained by using a “conservative” approach providing
high adequacy at the cost of some statistical power loss.
The transformation of these numerical variables into
dichotomized indicators (coded 1 or 0) also caused
information loss. On the other hand this enabled us
to focus on possible threshold effects when examining
e.g. the genetic effect on IS severity (by using NIHSS
cutpoints 0–7 vs. 8 or above, or 0–15 vs. 16 or above).S) and ten APOD and SIGMAR1 SNPs
f medium-severe
(NIHSS ≥ 8)
NIHSS; dichotomous indicator of severe








5% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
.40-7.69) 0.462 –*) – –*) –
.81-1.17) 0.804 0.97 (0.75-1.25) 0.822 0.87 (0.64-1.17) 0.347
.46-0.91) 0.012 1.01 (0.66-1.56) 0.967 0.75 (0.48-1.27) 0.283
.81-1.21) 0.922 0.94 (0.71-1.25) 0.664 0.84 (0.61-1.16) 0.290
.90-1.27) 0.457 0.79 (0.61-1.03) 0.084 0.77 (0.57-1.03) 0.079
.40-1.36) 0.327 0.97 (0.45-2.12) 0.948 1.17 (0.50-2.73) 0.722
.34-5.79) 0.641 –*) – –*) –
.94-1.25) 0.280 1.16 (0.95-1.42) 0.154 1.20 (0.96-1.50) 0.116
.72-1.00) 0.044 0.84 (0.66-1.06) 0.135 0.70 (0.54-0.92) 0.009
.85-1.19) 0.965 1.06 (0.83-1.34) 0.658 0.96 (0.73-1.25) 0.736
tudy on Ischaemic Stroke.
tients with NIHSS score of 16 or above.
Table 4 Detailed assessment of possible association between stroke severity (NIHSS) and SNP rs7659 within APOD
NIHSS score NIHSS; dichotomous indicator of medium-severe
(vs. mild) ischemic stroke onset (NIHSS ≥ 8)
NIHSS; dichotomous indicator of severe












OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Total -0.048 0.023 0.89 (0.77-1.04) 0.141 0.85 (0.72-1.00) 0.044 0.84 (0.66-1.06) 0.135 0.70 (0.54-0.92) 0.009
(N = 2221) 1676 controls 1618 controls 2023 controls 1947 controls
545 cases 495 cases 198 cases 166 cases
Males -0.055 0.053 0.89 (0.72-1.11) 0.293 0.85 (0.68-1.06) 0.143 0.82 (0.58-1.17) 0.273 0.75 (0.52-1.10) 0.144
(N = 1232) 971 controls 939 controls 1146 controls 1105 controls
261 cases 243 cases 86 cases 77 cases
Females -0.040 0.209 0.90 (0.73-1.11) 0.311 0.85 (0.68-1.07) 0.168 0.85 (0.62-1.16) 0.311 0.66 (0.46-0.96) 0.028
(N = 989) 705 controls 679 controls 877 controls 842 controls
284 cases 252 cases 112 cases 89 cases
LSR -0.054 0.026 0.87 (0.73-1.03) 0.113 0.81 (0.67-0.98) 0.026 0.79 (0.61-1.03) 0.081 0.65 (0.48-0.88) 0.005
(N = 1683) 1263 controls 1204 controls 1523 controls 1450 controls
420 cases 377 cases 160 cases 133 cases
SAHLSIS -0.032 0.454 0.97 (0.71-1.33) 0.858 0.94 (0.68-1.30) 0.702 1.03 (0.62-1.73) 0.902 0.86 (0.48-1.53) 0.605
(N = 538) 413 controls 412 controls 500 controls 497 controls
125 cases 118 cases 38 cases 33 cases
Age < 70 -0.066 0.029 0.89 (0.70-1.13) 0.333 0.85 (0.67-1.09) 0.201 0.98 (0.66-1.47) 0.940 0.81 (0.51-1.27) 0.348
(N = 1084) 868 controls 853 controls 1021 controls 1001 controls
216 cases 202 cases 63 cases 54 cases
Age≥ 70 -0.042 0.156 0.88 (0.72-1.08) 0.215 0.82 (0.66-1.02) 0.080 0.76 (0.57-1.01) 0.060 0.63 (0.45-0.88) 0.006
(N = 1137) 808 controls 750 controls 1002 controls 946 controls
329 cases 266 cases 135 cases 112 cases
LVD -0.008 0.918 1.14 (0.70-1.87) 0.597 0.97 (0.57-1.66) 0.924 1.20 (0.54-2.67) 0.651 0.53 (0.17-1.65) 0.272
(N = 185) 133 controls 128 controls 170 controls 163 controls
52 cases 45 cases 15 cases 10 cases
SVD -0.019 0.667 0.77 (0.46-1.30) 0.329 0.81 (0.47-1.38) 0.432 N/A N/A
(N = 500) 461 controls 452 controls
39 cases 38 cases
CE -0.076 0.065 0.89 (0.70-1.15) 0.367 0.78 (0.59-1.03) 0.081 0.72 (0.52-1.00) 0.051 0.59 (0.40-0.85) 0.005
(N = 595) 364 controls 338 controls 484 controls 448 controls
231 cases 204 cases 111 cases 94 cases
Ischemic stroke patients from Lund Stroke Register (LSR) and the Sahlgenska Academy Study on Ischemic Stroke (SAHLSIS).
NIHSS = NIH stroke scale. Multiple logistic regression models are controlling for covariates age, gender, diabetes mellitus, hypertension and current smoking when
analyzing the entire sample as well as separate study groups and age groups. When analyzing males and females separately the covariate gender is omitted from
these multivariable models. Pathogenetic ischemic stroke subtype: LVD = Large vessel disease; SVD = Small vessel disease; CE = Cardioembolic stroke. N/A = not
applicable due to absence of sampling units with NIHSS ≥ 16.
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two polymorphisms that have a strong influence in
CNS disease, namely rs1799729 (GC-241-240TT) and
rs1800866 (Gln2Pro) that show LD forming haplotypes
GC-Q and TT-P [39-41]. The rs1799729 is found in the
proximal promoter region while rs1800866 is present in
the first exon. Only rs1800866 was analysed in our study
but these two SNPs are closely related (nearly in completeLD with r2 = 0.98) and have been reported to be associated
with neuroprotection and risk of AD [41], and also risk of
depression and alcoholism [38,40]. The polymorphism
Gln2Pro is located in the amino acid sequence motif
MQWAVGRR [53] at the N-terminal part of the protein,
which is an endoplasmatic binding region. Hence, a
mutation could affect trafficking of SIGMAR1 associated
processes, which have been implicated in rodent models
Table 5 Analysis of association between outcome after stroke (shown by modified Rankin Scale, mRS) and ten APOD and SIGMAR1 SNPs
Deceased patients are not included in mRS: Deceased patients are included in mRS:
Ordinal score: Dichotomous indicator for dependence of support: Ordinal score: Dichotomous indicator for dependence of support:
SNP Estimated
Spearman’s Rho
P-value Simple logistic regression Multiple logistic regression Estimated
Spearman’s Rho
P-value Simple logistic regression Multiple logistic regression
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
SIGMAR1:
rs11559048 0.045 0.081 3.35 (0.80-14.1) 0.099 2.75 (0.49-15.3) 0.249 0.026 0.286 2.64 (0.63-11.1) 0.185 2.29 (0.38-13.7) 0.364
rs1800866 0.011 0.655 1.13 (0.93-1.37) 0.231 1.10 (0.88-1.36) 0.404 0.004 0.872 1.08 (0.90-1.30) 0.402 1.06 (0.85-1.31) 0.612
rs12001648 -0.012 0.631 0.94 (0.67-1.32) 0.712 0.77 (0.53-1.11) 0.165 -0.001 0.963 0.98 (0.72-1.34) 0.892 0.75 (0.53-1.07) 0.115
rs7036351 0.006 0.817 1.10 (0.89-1.33) 0.390 1.03 (0.83-1.29) 0.781 -0.007 0.772 1.04 (0.86-1.25) 0.722 0.97 (0.79-1.21) 0.810
rs3808873 0.021 0.436 1.08 (0.90-1.29) 0.392 1.11 (0.91-1.35) 0.290 0.012 0.636 1.05 (0.89-1.24) 0.598 1.07 (0.89-1.30) 0.457
APOD:
rs76929107 0.002 0.947 0.98 (0.54-1.78) 0.943 0.95 (0.49-1.82) 0.868 -0.013 0.582 0.87 (0.49-1.54) 0.623 0.92 (0.48-1.73) 0.790
rs5952 0.016 0.520 1.98 (0.28-14.1) 0.494 2.90 (0.32-26.7) 0.346 0.025 0.306 2.35 (0.39-14.1) 0.350 3.09 (0.35-27.5) 0.312
rs34697430 -0.019 0.460 0.91 (0.78-1.06) 0.221 0.91 (0.77-1.07) 0.243 0.002 0.946 0.96 (0.83-1.10) 0.514 0.92 (0.79-1.08) 0.295
rs7659 0.002 0.929 1.03 (0.88-1.22) 0.684 0.98 (0.82-1.17) 0.832 -0.005 0.846 1.02 (0.87-1.18) 0.842 0.96 (0.81-1.14) 0.665
rs823510 0.012 0.653 1.01 (0.85-1.21) 0.882 1.02 (0.84-1.23) 0.871 -0.008 0.742 0.97 (0.82-1.14) 0.696 0.97 (0.81-1.17) 0.764
Ischemic stroke patients from Lund Stroke Register and the Sahlgenska Academy Study on Ischemic Stroke.
mRS =modified Rankin Scale. Ordinal score comprises distinguishable categories 0–2, 3, 4, 5 and, if deceased patients are included, also category 6. Correspondingly, dichotomous indicator comprises categories 0–2 as
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http://www.biomedcentral.com/1471-2377/14/191of stroke [37]. However; we could not find any association
between the SIGMAR1 polymorphisms and stroke
risk, severity or recovery. The significance of the weak
association of rs12001648 needs further investigation.
Although rigorous statistical analysis did not provide
clear evidence of an association between the APOD
SNPs and stroke risk, severity or outcome, the possible
genetic influence of polymorphism rs7659 is interesting
and potentially relevant. Rs7659 is located in the 3′UTR
of APOD, and a functional variant in this area might influ-
ence the transcription of the gene or mRNA splicing.
Indeed, this SNP appears to be positioned at a putative
binding site for the human splicing factor SR SC35 [54].
Also, it is previously shown that rs7659 may be associated
with early onset AD within the subgroup of patients
lacking the APOEε4 allele [28] and with long term
clinical outcome in schizophrenics [54]. Moreover, the
APOD gene is localized on chromosome 3q2.2-qter in
close proximity to the 3q25-26 region linked to AD
[24]. Hence, taking into consideration the association
between rs7659 to other CNS disease and our finding
of a possible association of rs7659 with stroke risk and
stroke severity, particularly among the elderly, this
strongly encourages further studies of rs7659.
Possible occurrence of false positive P-values was
supressed by Bonferroni correction. False negative re-
sults cannot be detected since we do not know the
infinite population behind our predetermined study
sample. By performing a post hoc power analysis
including stroke severity (from NIHSS case–control
calculations) we found rather modest statistical powers
(between 5% and 41%), indicating a weak incentive for
replicative studies to find an association between the
selected SNPs and stroke severity (and even outcome,
defined by the mRS nomenclature).Conclusion
In this first attempt to study if stroke repair mechanisms
linked to certain regions within the APOD and SIGMAR1
genes may also affect recovery from stroke and severity of
stroke, we performed a candidate gene study including
twelve SNPs from these two genetic regions.
Our data suggest that the rs7659 SNP within the
APOD gene could be associated with risk for stroke
and stroke severity at stroke onset. This mutation
may decrease the levels of APOD and thereby diminish its
protective cell signalling and antioxidant action. However,
these associations showed only modest statistical signifi-
cance, suggesting that our study may be underpowered
despite the large sample size.Competing interests
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